Bridgeway Capital Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bridgeway Capital Management’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-476	Closed	-$319K	–	1302
2025 Q4	$319K	Hold	476	–	–	0.01%	920
2025 Q3	$155K	Sell	476 -167	-26%	-$55.6K	﹤0.01%	1052
2025 Q2	$212K	Buy	643 +111	+21%	+$25.4K	0.01%	951
2025 Q1	$142K	Buy	532 +70	+15%	+$21.4K	﹤0.01%	988
2024 Q4	$173K	Buy	462 +20	+5%	+$6.01K	﹤0.01%	1034
2024 Q3	$68.7K	Sell	442 -250	-36%	-$35.8K	﹤0.01%	1193
2024 Q2	$104K	Hold	692	–	–	﹤0.01%	1161
2024 Q1	$147K	Hold	692	–	–	﹤0.01%	1158
2023 Q4	$145K	Hold	692	–	–	﹤0.01%	1191
2023 Q3	$155K	Buy	692 +417	+152%	+$109K	﹤0.01%	1142
2023 Q2	$82.8K	Sell	275 -275	-50%	-$85.6K	﹤0.01%	1282
2023 Q1	$172K	Hold	550	–	–	﹤0.01%	1130
2022 Q4	$70.1K	Hold	550	–	–	﹤0.01%	1259
2022 Q3	$146K	Buy	+550	New	+$209K	﹤0.01%	1205

Other funds holding IRLA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bridgeway Capital Management's IRLA Position: Q1 2026 in Review

Bridgeway Capital Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 476 shares — an estimated $319K sold.

Bridgeway Capital Management first reported a position in IRLA in Q3 2022 and held it in 14 quarters. The position peaked at $319K in Q4 2025. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

Bridgeway Capital Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
Bridgeway Capital Management sold 476 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $319K.
Bridgeway Capital Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2022 and held it in 14 quarters.
Bridgeway Capital Management's IRulya Therapeutics Inc. Common Stock position peaked at $319K in Q4 2025.
43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.